|
gptkbp:instanceOf
|
biotechnology company
|
|
gptkbp:acquisition
|
gptkb:Aurelia_Bioscience
|
|
gptkbp:CEO
|
gptkb:Franz-Werner_Haas
|
|
gptkbp:clinicalTrials
|
gptkb:Argentina
gptkb:Australia
gptkb:Belgium
gptkb:Brazil
gptkb:Bulgaria
gptkb:Canada
gptkb:Chile
gptkb:China
gptkb:Colombia
gptkb:Croatia
gptkb:Denmark
gptkb:Egypt
gptkb:Finland
gptkb:France
gptkb:Germany
gptkb:Greece
gptkb:Hungary
gptkb:India
gptkb:Ireland
gptkb:Israel
gptkb:Italy
gptkb:Japan
gptkb:Malaysia
gptkb:Mexico
gptkb:Netherlands
gptkb:New_Zealand
gptkb:Norway
gptkb:Peru
gptkb:Philippines
gptkb:Portugal
gptkb:Romania
gptkb:Russia
gptkb:Saudi_Arabia
gptkb:Serbia
gptkb:Singapore
gptkb:Slovakia
gptkb:Slovenia
gptkb:South_Africa
gptkb:South_Korea
gptkb:Spain
gptkb:Sweden
gptkb:Switzerland
gptkb:Thailand
gptkb:Ukraine
gptkb:United_Arab_Emirates
gptkb:United_Kingdom
gptkb:United_States
gptkb:Vietnam
gptkb:Czech_Republic
gptkb:COVID-19_vaccine
Phase 2
Phase 3
therapeutic vaccines
prophylactic vaccines
|
|
gptkbp:collaborations
|
gptkb:Eli_Lilly
gptkb:AstraZeneca
gptkb:Boehringer_Ingelheim
gptkb:University_of_Pennsylvania
|
|
gptkbp:focus
|
mRNA technology
|
|
gptkbp:founded
|
2000
|
|
gptkbp:founder
|
gptkb:Ingmar_Hoerr
|
|
gptkbp:headquarters
|
gptkb:Tübingen,_Germany
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
CureVac
|
|
gptkbp:investmentFocus
|
$100 million
$200 million
$1.3 billion
|
|
gptkbp:notable_player
|
mRNA vaccine
|
|
gptkbp:notableEvent
|
CVnCoV
|
|
gptkbp:partnerships
|
gptkb:GSK
gptkb:Bayer_AG
gptkb:Pfizer
gptkb:Moderna
|
|
gptkbp:patentCitation
|
vaccine development
mRNA-based therapies
|
|
gptkbp:platforms
|
CureVac's_mRNA_technology
|
|
gptkbp:provides_access_to
|
gptkb:NASDAQ
|
|
gptkbp:regulatoryCompliance
|
gptkb:FDA
gptkb:European_Medicines_Agency
|
|
gptkbp:research_areas
|
oncology
autoimmune diseases
infectious diseases
|
|
gptkbp:technology
|
messenger RNA
|